IP Library Granted Patent US 10,774,079
Granted Patent B2
US 10,774,079 · App. 16/535,489 · Granted Sep 15, 2020

Quinazoline derivative

Inventors: Ying Shi (Shijiazhuang, CN); Qingzhi Gao (Shijiazhuang, CN); Xiaozhuo Chen (Shijiazhuang, CN); Yi Mi (Shijiazhuang, CN); Yaran Zhang (Shijiazhuang, CN); Hanyu Yang (Shijiazhuang, CN); Yujie Chen (Shijiazhuang, CN); Chunlei Liu (Shijiazhuang, CN); Guorui Mi (Shijiazhuang, CN); Yuxiu Ma (Shijiazhuang, CN); Dongmin Shen (Shijiazhuang, CN); Yang Guo (Shijiazhuang, CN); Linjing Fan (Shijiazhuang, CN)
Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
C07D417/12A61K31/517A61P35/00C07D239/94C07D401/12C07D403/12C07D405/12C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,774,079
App. No.
16/535,489
Filed
Aug 8, 2019
Granted
Sep 15, 2020
Kind
B2
Examiner
WARD, PAUL V
Art Unit
1624
USPC
544/293
Abstract

Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

Claims (35)

1. A method for the treatment of cancer comprising administering a therapeutically effect amount of a compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof to a subject having cancer;

wherein the cancer is selected from the group consisting of

thyroid cancer,

melanoma,

colon cancer,

gastric carcinoma, and

esophagus cancer,

wherein said compound is a compound of formula (I):

wherein

R 1 is —O(CH 2 ) n R 3 ,

wherein

n is 3, 4 or 5, and

R 3 is —NR e R f ,

wherein Re and R f are each independently selected from the group consisting of C 1-6 alkyl, or R e and R f are taken together to form —(CH 2 ) 4 —; and

R 2 is

2. The method of claim 1 , wherein R e and R f are methyl.

3. The method of claim 2 , wherein R 1 is selected from:

4. The method of claim 1 , wherein said compound is selected from the group consisting of:

5. The method of claim 4 , wherein the cancer is selected from the group consisting of

thyroid cancer caused by RET C634W mutation,

melanoma caused by KDR expressing, and

colon cancer caused by expressing both c-KIT and PDGFR.

6. A method for inhibiting the activity of a cell, comprising contacting a compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof with the cell,

wherein said compound is a compound of formula (I):

wherein

R 1 is —O(CH 2 ) n R 3 ,

wherein

n is 3, 4 or 5, and

R 3 is —NR e R f ,

wherein R e and R f are each independently selected from the group consisting of C 1-6 alkyl, or R e and R f are taken together to form —(CH 2 ) 4 —; and

R 2 is

wherein the cell is a human colon carcinoma cell, human epidermoid carcinoma cell, human esophageal carcinoma cell, human gastric carcinoma cell, human hepatoma carcinoma cell, human lung carcinoma cell, human melanoma cell, human non-small-cell lung carcinoma cell, human ovarian carcinoma cell, human pancreatic carcinoma cell, human renal carcinoma cell, human thyroid carcinoma cell, or human umbilical vein endothelial cell.

7. The method of claim 6 , wherein R e and R f are methyl.

8. The method of claim 7 , wherein R 1 is selected from:

9. The method of claim 6 , wherein said compound is selected from the group consisting of:

Priority Claims (1)
CN 2014 1 0391653 · Aug 11, 2014 · national
Continuity (2)
Division 15503323
Related Publication 20190367500A1 · Dec 5, 2019